We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and commercializing novel cancer therapeutics which reactivate the mutant tumor suppressor protein, p53. The Company's lead drug candidate, APR-246, a first-in-class small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes, acute myeloid leukemia as well as additional hematologic and solid tumor malignancies. Aprea Therapeutics Inc. is based in Boston, Massachusetts.
- Recent APRE Stock Price: $6.07
- Yearly Gain for APRE stock: 29.15%
- Market Cap for APRE stock: $22.68M
- P/E Ratio for APRE stock: 0.49
Will APRE's stock price go up? Is there an accurate APRE stock forecast available?
TipRanks.com reports that Aprea Therapeutics, Inc. currently has 3 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $15.67. The target pricing ranges from a high APRE forecast of $20 down to a low forecast of $11. Aprea Therapeutics, Inc. (APRE)’s last closing stock price was $6.07 which would put the average price target at 158.10% upside.
In addition, TradingView issued a sell rating for APRE stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on APRE stock.
Other analysts covering APRE include:
- Joseph Pantginis of H.C. Wainwright issued a Buy rating with the price target of $20 on 1 day ago
- Jason McCarthy of Maxim Group issued a Buy rating with the price target of $16 on 1 week ago
If you are wondering if APRE is a good stock to buy, here are 3rd party ratings for APRE stock:
- TipRanks.com: Buy
- TradingView.com: sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Sell, Top 33% (84 out of 252)
What is the sentiment on the street regarding Aprea Therapeutics, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for APRE stock: Bullish
- Blogger Consensus for APRE stock:
- Media Buzz for APRE stock: Neutral
- Insider Signal for APRE stock: Selling
- Investor Sentiment for APRE stock: Positive
- Hedge Fund signal for APRE stock: High Risk
The stock market is extremely volatile, and you need to do your own research on APRE stock including scouring the social networks like APRE StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for APRE stock chart >>
Summary: Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as Oncobiologics Inc., is based in Cranbury, United States.
- Recent OTLK Stock Price: $9.37
- Yearly Gain for OTLK stock: -53.61%
- Market Cap for OTLK stock: $121.93M
- P/E Ratio for OTLK stock: -2.34
Will OTLK's stock price go up? Is there an accurate OTLK stock forecast available?
TipRanks.com reports that Outlook Therapeutics, Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $42.00. The target pricing ranges from a high OTLK forecast of $60 down to a low forecast of $25. Outlook Therapeutics, Inc. (OTLK)’s last closing stock price was $9.37 which would put the average price target at 348.24% upside.
In addition, TradingView issued a buy rating for OTLK stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on OTLK stock.
Other analysts covering OTLK include:
- Douglas Tsao of H.C. Wainwright issued a Buy rating with the price target of $30 on 2 days ago
- Tim Chiang of Capital One Financial issued a Buy rating with the price target of $25 on 3 days ago
- Edward Woo of Ascendiant issued a Buy rating with the price target of $45 on 1 month ago
- Daniil Gataulin of Chardan Capital issued a Buy rating with the price target of $60 on 1 month ago
If you are wondering if OTLK is a good stock to buy, here are 3rd party ratings for OTLK stock:
- TipRanks.com: Buy
- TradingView.com: buy
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 33% (84 out of 252)
What is the sentiment on the street regarding Outlook Therapeutics, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for OTLK stock: Bearish
- Blogger Consensus for OTLK stock:
- Media Buzz for OTLK stock: Sell
- Insider Signal for OTLK stock: Selling
- Investor Sentiment for OTLK stock: Negative
- Hedge Fund signal for OTLK stock: High Risk
The stock market is extremely volatile, and you need to do your own research on OTLK stock including scouring the social networks like OTLK StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for OTLK stock chart >>
Summary: Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.
- Recent DCTH Stock Price: $5.09
- Yearly Gain for DCTH stock: -15.17%
- Market Cap for DCTH stock: $112.21M
- P/E Ratio for DCTH stock: -1.48
Will DCTH's stock price go up? Is there an accurate DCTH stock forecast available?
TipRanks.com reports that Delcath Systems, Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $17.50. The target pricing ranges from a high DCTH forecast of $21 down to a low forecast of $13. Delcath Systems, Inc. (DCTH)’s last closing stock price was $5.09 which would put the average price target at 243.81% upside.
In addition, TradingView issued a buy rating for DCTH stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on DCTH stock.
Other analysts covering DCTH include:
- William Maughan of Canaccord Genuity issued a Buy rating with the price target of $21 on 1 day ago
- Marie Thibault of BTIG issued a Buy rating with the price target of $16 on 1 day ago
- Scott Henry of Alliance Global Partners issued a Buy rating with the price target of $13 on 7 months ago
If you are wondering if DCTH is a good stock to buy, here are 3rd party ratings for DCTH stock:
- TipRanks.com: Buy
- TradingView.com: buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 26% (66 out of 252)
What is the sentiment on the street regarding Delcath Systems, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for DCTH stock: Bullish
- Blogger Consensus for DCTH stock:
- Media Buzz for DCTH stock: Sell
- Insider Signal for DCTH stock: Selling
- Investor Sentiment for DCTH stock: Positive
- Hedge Fund signal for DCTH stock: High Risk
The stock market is extremely volatile, and you need to do your own research on DCTH stock including scouring the social networks like DCTH StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for DCTH stock chart >>
Summary: Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. Lucid Diagnostics Inc. is based in NEW YORK.
- Recent LUCD Stock Price: $0.99
- Yearly Gain for LUCD stock: -29.29%
- Market Cap for LUCD stock: $44.22M
- P/E Ratio for LUCD stock: -0.7
Will LUCD's stock price go up? Is there an accurate LUCD stock forecast available?
TipRanks.com reports that Lucid Diagnostics Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $4.20. The target pricing ranges from a high LUCD forecast of $8.5 down to a low forecast of $2.5. Lucid Diagnostics Inc. (LUCD)’s last closing stock price was $0.99 which would put the average price target at 324.24% upside.
In addition, TradingView issued a sell rating for LUCD stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on LUCD stock.
Other analysts covering LUCD include:
- Charles Duncan of Cantor Fitzgerald issued a Buy rating with the price target of $3 on 1 day ago
- Anthony Vendetti of Maxim Group issued a Buy rating with the price target of $4 on 1 day ago
- Kyle Mikson CFA of Canaccord Genuity issued a Buy rating with the price target of $3 on 3 months ago
- Edward Woo of Ascendiant issued a Buy rating with the price target of $8.5 on 3 months ago
If you are wondering if LUCD is a good stock to buy, here are 3rd party ratings for LUCD stock:
- TipRanks.com: Buy
- TradingView.com: sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 26% (66 out of 252)
What is the sentiment on the street regarding Lucid Diagnostics Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for LUCD stock: Bearish
- Blogger Consensus for LUCD stock:
- Media Buzz for LUCD stock: Sell
- Insider Signal for LUCD stock: Buying
- Investor Sentiment for LUCD stock: Negative
- Hedge Fund signal for LUCD stock: High Risk
The stock market is extremely volatile, and you need to do your own research on LUCD stock including scouring the social networks like LUCD StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for LUCD stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================